Drug intelligence / Profile preview

arabinogalactan ICPA

Development stage
Preclinical
Administration
Oral
01

Overview

Arabinogalactan ICPA is a natural polysaccharide research compound isolated from the water extract of the medicinal and edible plant *Ixeris chinensis* (Thunb.) Nakai. It has a molecular weight of approximately 58.1 kDa and is primarily composed of galactose and arabinose. ICPA exhibits significant immunomodulatory activity, including the stimulation of macrophage proliferation and the regulation of cytokine production. In preclinical models of ulcerative colitis (UC), ICPA has been shown to ameliorate symptoms such as weight loss and colon shortening by inhibiting pro-inflammatory mediators like TNF-α, IL-1β, and the NLRP3 inflammasome, while promoting the anti-inflammatory cytokine IL-10. Furthermore, it restores intestinal barrier integrity by upregulating tight junction proteins (ZO-1 and occludin) and modulates gut microbiota by increasing the abundance of *Turicibacter* and *Bifidobacterium*. It has also been investigated as a stabilizer for selenium nanoparticles to enhance anti-tumor activity in hepatocellular carcinoma.

Other names
Ixeris chinensis polysaccharide arabinogalactanICPA polysaccharide
02

Targets

IL1B (Interleukin-1 beta)IL10 (Interleukin-10)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)OCLN (Occludin)TJP1 (Tight junction protein 1 (ZO-1))TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on arabinogalactan ICPA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on arabinogalactan ICPA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call